AU2600800A - Promotion or inhibition of angiogenesis and cardiovascularization - Google Patents

Promotion or inhibition of angiogenesis and cardiovascularization

Info

Publication number
AU2600800A
AU2600800A AU26008/00A AU2600800A AU2600800A AU 2600800 A AU2600800 A AU 2600800A AU 26008/00 A AU26008/00 A AU 26008/00A AU 2600800 A AU2600800 A AU 2600800A AU 2600800 A AU2600800 A AU 2600800A
Authority
AU
Australia
Prior art keywords
cardiovascularization
angiogenesis
promotion
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU26008/00A
Inventor
Avi J. Ashkenazi
Kevin P. Baker
Napoleone Ferrara
Hanspeter Gerber
Audrey Goddard
Paul J. Godowski
Austin L. Gurney
Kenneth J. Hillan
Sophia S. Kuo
Melanie R Mark
Scot A. Marsters
Nicholas F. Paoni
Robert M. Pitti
Colin K. Watanabe
P. Mickey Williams
William I. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/005028 external-priority patent/WO1999046281A2/en
Priority claimed from PCT/US1999/012252 external-priority patent/WO1999063088A2/en
Priority claimed from PCT/US1999/020111 external-priority patent/WO2000012708A2/en
Priority claimed from PCT/US1999/020594 external-priority patent/WO2000015666A2/en
Priority claimed from PCT/US1999/021547 external-priority patent/WO2000015797A2/en
Priority claimed from PCT/US1999/021090 external-priority patent/WO2000015796A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2600800A publication Critical patent/AU2600800A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU26008/00A 1999-03-08 2000-01-05 Promotion or inhibition of angiogenesis and cardiovascularization Abandoned AU2600800A (en)

Applications Claiming Priority (29)

Application Number Priority Date Filing Date Title
PCT/US1999/005028 WO1999046281A2 (en) 1998-03-10 1999-03-08 Novel polypeptides and nucleic acids encoding the same
WOUS9905028 1999-03-08
US12395799P 1999-03-12 1999-03-12
US60123957 1999-03-12
US13428799P 1999-05-14 1999-05-14
US60134287 1999-05-14
PCT/US1999/012252 WO1999063088A2 (en) 1998-06-02 1999-06-02 Membrane-bound proteins and nucleic acids encoding the same
WOUS9912252 1999-06-02
US14103799P 1999-06-23 1999-06-23
US60141037 1999-06-23
US14475899P 1999-07-20 1999-07-20
US60144758 1999-07-20
US14569899P 1999-07-26 1999-07-26
US60145698 1999-07-26
WOUS9920111 1999-09-01
PCT/US1999/020111 WO2000012708A2 (en) 1998-09-01 1999-09-01 Further pro polypeptides and sequences thereof
PCT/US1999/020594 WO2000015666A2 (en) 1998-09-10 1999-09-08 Compositions and methods for the treatment of tumors
WOUS9920594 1999-09-08
PCT/US1999/021547 WO2000015797A2 (en) 1998-09-17 1999-09-15 Compositions and methods for the treatment of immune related diseases
WOUS9921090 1999-09-15
PCT/US1999/021090 WO2000015796A2 (en) 1998-09-16 1999-09-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
WOUS9921547 1999-09-15
WOUS9923089 1999-10-05
WOUS9928313 1999-11-30
WOUS9928409 1999-11-30
WOUS9928565 1999-12-02
WOUS9928564 1999-12-02
PCT/US2000/000219 WO2000053753A2 (en) 1999-03-08 2000-01-05 Promotion or inhibition of angiogenesis and cardiovascularization
USNOTGIVEN 2000-11-08

Publications (1)

Publication Number Publication Date
AU2600800A true AU2600800A (en) 2000-09-28

Family

ID=27537684

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26008/00A Abandoned AU2600800A (en) 1999-03-08 2000-01-05 Promotion or inhibition of angiogenesis and cardiovascularization

Country Status (2)

Country Link
AU (1) AU2600800A (en)
WO (1) WO2000053753A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2284550A1 (en) 1997-03-21 1998-10-01 Human Genome Sciences, Inc. 87 human secreted proteins
US20030069403A1 (en) 1997-06-16 2003-04-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7169906B2 (en) 1997-09-17 2007-01-30 Genentech, Inc. PRO211 polypeptides
US6974689B1 (en) 1997-09-18 2005-12-13 Genentech, Inc. Nucleic acid encoding PRO211 polypeptides
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
WO2000008057A2 (en) 1998-08-07 2000-02-17 Immunex Corporation Molecules designated b7l-1
US20020172678A1 (en) * 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
PT1247863E (en) * 1998-08-11 2006-05-31 Genentech Inc HOMOLOGO OF PROTEIN A OF COBRA POISON AND NUCLEIC ACID THAT CODES IT
US7264801B2 (en) 1998-08-11 2007-09-04 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and method of use
US6432673B1 (en) 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
DE60045681D1 (en) * 1999-03-11 2011-04-14 Merck Serono Sa VASCULAR ADHESION MOLECULES AND MODULATION OF THEIR FUNCTION
EP1196186B1 (en) * 1999-07-12 2007-10-31 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
AU6391000A (en) * 1999-07-28 2001-02-19 Genentech Inc. Method of preventing the injury or death of retinal cells and treating ocular diseases
WO2002002602A2 (en) * 2000-06-30 2002-01-10 Millennium Pharmaceuticals, Inc. Slgp protein and nucleic acid molecules and uses therefor
WO2002006483A1 (en) * 2000-07-18 2002-01-24 Takeda Chemical Industries, Ltd. Novel physiologically active peptide and use thereof
ES2338492T3 (en) * 2000-10-16 2010-05-07 Genentech, Inc. WIPS POLIPEPTIDES AND THERAPEUTIC APPLICATIONS OF THE SAME.
JP2004532609A (en) 2000-11-03 2004-10-28 ザ リージェント オブ ザ ユニバーシティ オブ カリフォルニア Prokineticin polypeptides, related compositions and methods
WO2002057443A1 (en) * 2001-01-22 2002-07-25 Takeda Chemical Industries, Ltd. Process for producing zaq ligand
IL159153A0 (en) * 2001-06-08 2004-06-01 Sankyo Co Methods for testing drugs for treating or preventing diseases such as hyperlipidemia
WO2003006687A2 (en) * 2001-07-10 2003-01-23 Medigene Ag Novel target genes for diseases of the heart
US20050123925A1 (en) * 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JPWO2003083114A1 (en) * 2002-03-28 2005-08-04 アステラス製薬株式会社 Angiopoietin-related growth factor
CN102225194B (en) 2003-03-12 2014-07-16 健泰科生物技术公司 Use of Bv8 and/or EG-VEGF to promote hematopoiesis
WO2006026222A2 (en) 2004-08-25 2006-03-09 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP1988768A2 (en) * 2006-02-17 2008-11-12 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900673A (en) * 1988-03-28 1990-02-13 President And Fellows Of Harvard College Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression
BR9507479A (en) * 1994-04-26 1997-09-16 Childrens Medical Center Angipstantine and process of use for inhibiting angiogenesis
ATE319827T1 (en) * 1995-11-17 2006-03-15 Asahi Chemical Ind POLYPEPTIDE THAT SUPPRESSES DIFFERENTIATION
JP3989589B2 (en) * 1997-05-14 2007-10-10 旭化成株式会社 Vascular cell regulator

Also Published As

Publication number Publication date
WO2000053753A3 (en) 2001-04-19
WO2000053753A2 (en) 2000-09-14

Similar Documents

Publication Publication Date Title
AU2600800A (en) Promotion or inhibition of angiogenesis and cardiovascularization
EP1196158A4 (en) Curcumin and curcuminoid inhibition of angiogenesis
AU6465400A (en) Inhibition of action potentials
AU4520801A (en) Novel substituted phenanthridinones and methods of use thereof
AU3791601A (en) Treatment of coal
AU7620200A (en) Compositions and methods relating to the inhibition of casomorphin and gluteomorphin
AU2596700A (en) Promotion or inhibition of angiogenesis and cardiovascularization
AU4717301A (en) Catheter assembly and method of use
AU2567300A (en) Inhibition of angiogenesis with epigallocatechin-3-gallate
AU3771000A (en) Method of promoting angiogenesis
AU6566098A (en) Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis
AUPQ429399A0 (en) Oxidized apolipoproteins and methods of use
AU9484398A (en) Promotion or inhibition of angiogenesis and cardiovascularization
IL140324A0 (en) Inhibition of transcription factor nf-kb
AU7601400A (en) Treatment and prevention of hepatic disorders
AU4369000A (en) Inhibition of complement action
AU4440199A (en) Methods and compositions for inhibition of angiogenesis
AU5571799A (en) Angiogenesis inhibitors and uses thereof
IL141537A0 (en) Promotion or inhibition of angiogenesis and cardiovascularization
PL352409A1 (en) Derivatives of 1-trifluorometyl-4-hydroxy-7-piperidinyl-aminomethylochromane
AUPQ180499A0 (en) Beta-amyloid peptide inhibitors
AU2002215032A1 (en) Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof
EP1229913A4 (en) Substituted 1-benzazepines and derivatives thereof
AU2001251631A1 (en) Hydrazide and alkoxyamide angiogenesis inhibitors
AU1747100A (en) Promotion or inhibition of angiogenesis and cardiovascularization

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase